Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05477186 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 185
- Enrollment target
NCT05477186: Completed Phase 1 study, sponsored by GlaxoSmithKline.
NCT05477186 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 185 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (208% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05477186, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 185 participants
- Enrollment target
Study Summary
Prevention of COVID-19 caused by SARS-CoV-2.
Primary Outcome
Assessed solicited local adverse events were injection site pain, redness, swelling, and Lymphadenopathy.
Interventions
- BIOLOGICAL CV0501 (3 μg)
- BIOLOGICAL CV0501 (6 μg)
- BIOLOGICAL CV0501 (12 μg)
- BIOLOGICAL CV0501 (25 μg)
- BIOLOGICAL CV0501 (50 μg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2022-08-12 |
| Est. Completion | 2023-08-18 |
| Phase | Phase 1 |
What the finished NCT05477186 record still lists
NCT05477186 is an interventional study that assigns participants to a tested intervention. The registered 185 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (208% higher).
The record links to 0 conditions, and to 5 interventions - of which CV0501 (3 μg) is the first listed.
NCT05477186 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05477186 about?
NCT05477186 is a clinical study titled "Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old". Prevention of COVID-19 caused by SARS-CoV-2.
What is the current status of trial NCT05477186?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 185 participants. The study started on 2022-08-12. Estimated completion is 2023-08-18.
What interventions are being tested in trial NCT05477186?
The interventions under investigation include: CV0501 (3 μg) (BIOLOGICAL), CV0501 (6 μg) (BIOLOGICAL), CV0501 (12 μg) (BIOLOGICAL), CV0501 (25 μg) (BIOLOGICAL), CV0501 (50 μg) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05477186?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05477186's enrollment target sits among peer trials
185 294th of 2000 higher than 1,707 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04041154 · 185 participants · NA
Behavioral and Neural Representations of Subjective Effort Cost
- NCT04484272 · 185 participants · NA
A Stress and Pain Self-management m-Health App for Adult Outpatients With Sickle Cell Disease
- NCT05020860 · 185 participants · Phase 2
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
- NCT05793541 · 185 participants · NA
Just-in-time Interventions for Reducing Short-term Suicide Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI